Novel protein disulfide isomerase inhibitor with anticancer activity in multiple myeloma

Cancer Research

Volumn 76, Issue 11, 2016, Pages 3340-3350

  Vatolin, Sergei ^a   Phillips, James G ^a   Jha, Babal K ^a   Govindgari, Shravya ^b   Hu, Jennifer ^c   Grabowski, Dale ^a   Parker, Yvonne ^a   Lindner, Daniel J ^a,c   Zhong, Fei ^d   Distelhorst, Clark W ^c,d   Smith, Mitchell R ^a,c   Cotta, Claudiu ^a   Xu, Yan ^e   Chilakala, Sujatha ^e   Kuang, Rebecca R ^f   Tall, Samantha ^g   Reu, Frederic J ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e CLEVELAND STATE UNIVERSITY   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CCF 642; ISOMERASE INHIBITOR; LOC 14; PACMA 31; PROTEIN DISULFIDE ISOMERASE; UNCLASSIFIED DRUG; CCF642; ENZYME INHIBITOR; THIAZOLIDINE DERIVATIVE; THIOKETONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; LIFESPAN; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENDOPLASMIC RETICULUM; ENZYMOLOGY; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PROTEIN CONFORMATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; BLOTTING, WESTERN; CELL PROLIFERATION; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITORS; HUMANS; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; OXIDATION-REDUCTION; PROTEIN CONFORMATION; PROTEIN DISULFIDE-ISOMERASES; THIAZOLIDINES; THIONES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84975044045     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3099     Document Type: Article

References (38)

1. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014;25:91-101.
2. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014;28:384-90.
3. Vincenz L, Jager R, O'Dwyer M, Samali A. Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma. Mol Cancer Ther 2013;12:831-43.
4. Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer 2014;14:581-97.
5. Masciarelli S, Sitia R. Building and operating an antibody factory: redox control during B to plasma cell terminal differentiation. Biochim Biophys Acta 2008;1783:578-88.
6. Ribatti D. Edelman's view on the discovery of antibodies. Immunol Lett 2015;164:72-5.
7. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005;115:2656-64.
8. Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol 2005;7:766-72.
9. Terada K, Manchikalapudi P, Noiva R, Jauregui HO, Stockert RJ, Schilsky ML. Secretion, surface localization, turnover, and steady state expression of protein disulfide isomerase in rat hepatocytes. J Biol Chem 1995;270:20410-6.
10. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013;24:289-304.
11. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
12. Galligan JJ, Petersen DR. The human protein disulfide isomerase gene family. Hum Genomics 2012;6:6.
13. Dallas SL, Garrett IR, Oyajobi BO, Dallas MR, Boyce BF, Bauss F, et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999;93:1697-706.
14. Garrett IR, Dallas S, Radl J, Mundy GR. A murine model of human myeloma bone disease. Bone 1997;20:515-20.
15. Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 2013;27:430-40.
16. Oyajobi BO, Deng JH, Dallas SL, Jenson HB, Mundy GR, Gao SJ. Absence of herpesvirus DNA sequences in the 5T murine model of human multiple myeloma. Br J Haematol 2000;109:413-9.
17. Raturi A, Mutus B. Characterization of redox state and reductase activity of protein disulfide isomerase under different redox environments using a sensitive fluorescent assay. Free Radic Biol Med 2007;43:62-70.
18. Wang C, Li W, Ren J, Fang J, Ke H, Gong W, et al. Structural insights into the redox-regulated dynamic conformations of human protein disulfide isomerase. Antioxid Redox Signal 2013;19:36-45.
19. Zhong F, Harr MW, Bultynck G, Monaco G, Parys JB, De Smedt H, et al. Induction of Ca(2)+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction. Blood 2011;117:2924-34.
20. Mazzaccara C, Labruna G, Cito G, Scarfo M, De Felice M, Pastore L, et al. Age-related reference intervals of the main biochemical and hematological parameters in C57BL/6J, 129SV/EV and C3H/HeJ mouse strains. PLoS One 2008;3:e3772.
21. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013;27:464-72.
22. Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, et al. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc Natl Acad Sci U S A 2012;109:16348-53.
23. Kaplan A, Gaschler MM, Dunn DE, Colligan R, Brown LM, Palmer AGIII, et al. Small molecule-induced oxidation of protein disulfide isomerase is neuroprotective. Proc Natl Acad Sci U S A 2015;112:E2245-52.
24. Xu S, Sankar S, Neamati N. Protein disulfide isomerase: a promising target for cancer therapy. Drug Discov Today 2014;19:222-40.
25. Kimura T, Nishida A, Ohara N, Yamagishi D, Horibe T, Kikuchi M. Functional analysis of the CXXC motif using phage antibodies that cross-react with protein disulphide-isomerase family proteins. Biochem J 2004;382:169-76.
26. Jaffrey SR, Snyder SH. The biotin switch method for the detection of S-nitrosylated proteins. Science's STKE 2001;2001:pl1.
27. Gardner BM, Walter P. Unfolded proteins are Ire1-activating ligands that directly induce the unfolded protein response. Science 2011;333:1891-4.
28. Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, et al. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood 2012;119:5772-81.
29. Schmidmaier R, Baumann P, Meinhardt G. Cell-cell contact mediated signalling - no fear of contact. Exp Oncol 2006;28:12-5.
30. Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC, et al. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia 2009;23:170-7.
31. Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R, et al. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 2008;7:1121-9.
32. Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, et al. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NFkappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia 2007;21:1521-31.
33. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010;16:483-9.
34. Santhi K, Dhanaraj SA, Koshy M, Ponnusankar S, Suresh B. Study of biodistribution of methotrexate-loaded bovine serum albumin nanospheres in mice. Drug Dev Ind Pharm 2000;26:1293-6.
35. Wosikowski K, Biedermann E, Rattel B, Breiter N, Jank P, Loser R, et al. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells. Clin Cancer Res 2003;9:1917-26.
36. Bose P, Batalo MS, Holkova B, Grant S. Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opin Pharmacother 2014:15:2443-59.
37. Frand AR, Kaiser CA. The ERO1 gene of yeast is required for oxidation of protein dithiols in the endoplasmic reticulum. Mol Cell 1998;1:161-70.
38. Baksh S, Burns K, Andrin C, Michalak M. Interaction of calreticulin with protein disulfide isomerase. J Biol Chem 1995;270:31338-44.